Abstracts tagged "Lupus nephritis"

Abstract Number: 2452 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Sanbin Wang¹, Heng Mei², Dongmei Zhou³, Wei Xie², Songlou Yin³, Chunmei Liu³, Hanwei Wang⁴, Huan Zhou⁵, Yue Xie⁶, Lu Han⁷, Jiangtao Ren⁸, Yali Zhou⁸, Wengang Ge⁷ and Jan Davidson-Moncada⁸, ¹⁹²⁰th Hospital of Joint Logistic Support Force, Kunming, China (People's Republic), ²Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ³The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China (People's Republic), ⁴The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), ⁶Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ⁷Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁸Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…
Abstract Number: 1846 • ACR Convergence 2025
Integrated spatial and single-cell profiling of treatment-naïve lupus nephritis biopsies
Roopa Madhu¹, Rachael Bogle², DANIEL STEIN³, JIngyi Cao⁴, Alex Tsoi², Caleb Marlin⁵, Thomas Eisenhaure⁶, Peter Izmirly⁷, Mala Masson⁸, Kevin Wei⁹, Victoria Werth¹⁰, Jennifer Barnas¹¹, Michael Brenner¹², Judith James⁵, Johann Gudjonsson¹³, Joel Guthridge⁵, Nir Hacohen¹⁴, Kelly Ruggles¹⁵, Soumya Raychaudhuri¹⁶, Jill Buyon¹⁷, Michelle Petri¹⁸, Brad Rovin¹⁹, Andrea Fava²⁰ and ilya Korsunsky¹⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²University of Michigan, Holland, OH, ³Harvard University, Boston, ⁴BWH, Boston, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Broad Institute, Cambridge, MA, ⁷New York University Grossman School of Medicine, New York, NY, ⁸NYU Langone Health, New York, ⁹Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹⁰University of Pennsylvania, Wynnewood, PA, ¹¹University of Rochester, Rochester, NY, ¹²Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Broad Institute of MIT Harvard, Cambridge, MA, ¹⁵NYU Grossman School of Medicine, Brooklyn, NY, ¹⁶Brigham and Women's Hospital, Boston, MA, ¹⁷NYU Grossman School of Medicine, New York, NY, ¹⁸Johns Hopkins University School of Medicine, Timonium, MD, ¹⁹The Ohio State University, Columbus, OH, ²⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation and leads to loss of kidney function. Depending on race/ethnicity, up to 60% of Systemic Lupus…
Abstract Number: 1526 • ACR Convergence 2025
Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
Ed Vital¹, George Bertsias², Andrea Doria³, Sindhu Johnson⁴, Sarah Mackie⁵, Sandra Navarra⁶, Bas Nijmeijer⁷, Ayobami Olojo⁷, Bernardo A. Pons-Estel⁸, Onno Teng⁹ and Jinoos Yazdany¹⁰, ¹University of Leeds, Leeds, England, United Kingdom, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³University of Padova, Padova, Italy, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Leeds, Leeds, United Kingdom, ⁶University of Santo Tomas, Manila, Philippines, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ⁹Leiden University Medical Center, Leiderdorp, Netherlands, ¹⁰UCSF, San Francisco, CA
Background/Purpose: Despite guidelines for SLE emphasizing the importance of tapering corticosteroids (CS), detailed recommendations on how to taper are limited. The purpose of this modified…
Abstract Number: 1078 • ACR Convergence 2025
Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023
Muhammad Sohaib Asghar¹, Mohammed Akram², Veerkaran Banga¹, rajkaran Banga¹, Woo Joo Lee¹, Afsana Ansari Shaik³, Syed Muhammad Muneeb Akhtar⁴ and Thomas Shimshak¹, ¹AdventHealth Sebring, Sebring, FL, ²HCA Aventura, Aventura, FL, ³Mayo Clinic, Rochester, MN, ⁴Dow University of Health Sciences, Karachi, Pakistan
Background/Purpose: Lupus is a systemic autoimmune disease that occurs when the body's immune system attacks its own tissues and organs. This study was conducted to…
Abstract Number: 0651 • ACR Convergence 2025
The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
Braden Zeno¹, Tim Alexandrov², Hongyu Yuan³, Shane Bruckner³ and Wael Jarjour², ¹Ohio State University, upper arlington, OH, ²The Ohio State University, Columbus, OH, ³OSU, Columbus, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes inflammation in many of the body’s tissues, including the skin, joints, lungs, kidneys…
Abstract Number: 0842 • ACR Convergence 2025
Association of urinary biomarkers with histological features in diagnostic and per-protocol repeat kidney biopsies in lupus nephritis
Andrea Fava¹, CHEN-YU LEE¹, Carla Guthridge², Dionysis Nikolopoulos³, Julius Lindblom⁴, Farah Tamirou⁵, Michelle Petri⁶, Joel Guthridge², Frederic Houssiau⁷ and Ioannis Parodis⁸, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Cliniques universitaires Saint-Luc, Brussels, Belgium, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷CUSL, BRUSSELS, Belgium, ⁸Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Persistent intrarenal inflammation despite immunosuppression drives kidney damage and functional decline in lupus nephritis (LN). Yet, current guidelines do not recommend repeat biopsy to…
Abstract Number: 2448 • ACR Convergence 2025
Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Haiting Wang¹, Liling Zhao², Shuang Ye³ and Shaoying Yang², ¹Renji Hospital, Rockville, MD, ²Renji hospital, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX…
Abstract Number: 1843 • ACR Convergence 2025
Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Norio Hanata¹, Carmelo Carmona-Rivera¹, Victoria Hoffman², Kan Jiang³, davide Randazzo⁴, Meryl Waldman⁵, Sarfaraz Hasni⁶ and Mariana Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ³Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Bethesda, PA, ⁶National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease that frequently affects the kidneys, with lupus nephritis (LN) being a major contributor to morbidity…
Abstract Number: 1522 • ACR Convergence 2025
Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Carlos Pena¹, Irene Tan², Rafal Ali³, Arthur Lau⁴, Shahrzad Abdollahi⁵, Fabian Rodriguez Quinonez⁶ and Marianne Meshreky⁷, ¹Jefferson Einstein Philadelphia, Wynnewood, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA, ³Jefferson Einstein Philadelphia, Lansdale, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Jefferson Einstein Hospital, Philadelphia, PA, ⁶Einstein Medical Center Philadelphia, Philadelphia, PA, ⁷St. Mary's Hospital, Philadelphia
Background/Purpose: Evidence of kidney disease occurs in up to one half of patients with SLE, and approximately 10% of the patients with lupus nephritis (LN)…
Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Anisha Patel¹, Alexandra Miller¹, Lisa Lindsay¹, Danny Sheinson¹, Zhiyu Xia¹, William Pendergraft¹ and Maria Dall'Era², ¹Genentech, Inc., South San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
Abstract Number: 0841 • ACR Convergence 2025
Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study
Kinga Grzybowski¹ and Irene Tan², ¹Jefferson Einstein Montgomery Hospital, Maspeth, NY, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Lupus Nephritis (LN) is one of the most serious complications of SLE (Systemic Lupus Erythematosus) characterized by an attack of the kidneys by the…
Abstract Number: 2439 • ACR Convergence 2025
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Ahmad Alomari¹, Nikita Shah², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/HCA Florida North Florida Hospital, Gainesville, FL, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…
Abstract Number: 1844 • ACR Convergence 2025
Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
Paul Hoover¹, Rollin Leavitt², Jill Buyon³, Jennifer Anolik⁴, Jennifer Barnas⁵, Judith James⁶, Joel Guthridge⁶, Michelle Petri⁷, Betty Diamond⁸, Soumya Raychaudhuri¹, Nir Hacohen⁹, Anne Davidson¹⁰ and Arnon Arazi¹¹, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, MA, ³NYU Grossman School of Medicine, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵University of Rochester, Rochester, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸The Feinstein Institutes for Medical Research, Manhasset, NY, ⁹Broad Institute, Cambridge, MA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹The Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: In collaboration with the AMP-RA/SLE network, we identified disease-associated macrophages (D-Macs) in kidney biopsies from 155 patients with active lupus nephritis (LN) and 30…
Abstract Number: 1521 • ACR Convergence 2025
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad Rovin¹, William Pendergraft², Liz Lightstone³, Eric Daugas⁴, Richard Furie⁵, Theodore Omachi², Imran Hassan⁶, Elsa Martins⁷, Thomas Schindler⁷, Jay Garg², Luis Quintana⁸, Piotr Leszczyński⁹ and Ana Malvar¹⁰, ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁴Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Department of Nephrology, Hospital Clinic, Barcelona, Spain, ⁹Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…

« Previous Page
1
…
3
4
5
6
7
…
44
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].